This article was downloaded by:
On: *22 January 2011*
Access details: *Access Details: Free Access*
Publisher *Taylor & Francis*
Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK

Journal of Asian Natural Products Research
Publication details, including instructions for authors and subscription information:
http://www.informaworld.com/smpp/title~content=t713454007

Triterpenes from *Astilbe chinensis*

Jun-Yi Hu[ab]; Zhi Yao[c]; Ying-Qian Xu[b]; Yoshihisa Takaishi[d]; Hong-Quan Duan[a]
[a] School of Pharmaceutical Sciences, Research Center of Basic Medical Sciences, Tianjin Medical University, Tianjin, China [b] School of Chemical Engineering, University of Science and Technology Liaoning, Anshan, Liaoning, China [c] Department of Immunology, Tianjin Medical University, Tianjin, China [d] Faculty of Pharmaceutical Sciences, University of Tokushima, Tokushima, Japan

To cite this Article Hu, Jun-Yi , Yao, Zhi , Xu, Ying-Qian , Takaishi, Yoshihisa and Duan, Hong-Quan(2009) 'Triterpenes from *Astilbe chinensis*', Journal of Asian Natural Products Research, 11: 3, 236 — 242
To link to this Article: DOI: 10.1080/10286020802682866
URL: http://dx.doi.org/10.1080/10286020802682866

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: http://www.informaworld.com/terms-and-conditions-of-access.pdf

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

Journal of Asian Natural Products Research
Vol. 11, No. 3, March 2009, 236–242

Taylor & Francis
Taylor & Francis Group

Triterpenes from *Astilbe chinensis*

Jun-Yi Hu[ab], Zhi Yao[c], Ying-Qian Xu[b], Yoshihisa Takaishi[d] and Hong-Quan Duan[a]*

[a]*School of Pharmaceutical Sciences, Research Center of Basic Medical Sciences, Tianjin Medical University, Tianjin, China;* [b]*School of Chemical Engineering, University of Science and Technology Liaoning, Anshan, Liaoning, China;* [c]*Department of Immunology, Tianjin Medical University, Tianjin, China;* [d]*Faculty of Pharmaceutical Sciences, University of Tokushima, Tokushima, Japan*

(*Received 2 September 2008; final version received 26 November 2008*)

Six new triterpenes, 3β,6β-dihydroxyurs-12-en-27-oic acid (**1**), 3β,6β,24-trihydroxyurs-12-en-27-oic acid (**2**), 3β,6β,7α-trihydroxyurs-12-en-27-oic acid (**3**), 3β-acetoxy-6β-hydroxyurs-12-en-27-oic acid (**4**), 3β,6β,24-trihydroxyolean-12-en-27-oic acid (**5**), and 3β,6β,7α-trihydroxyolean-12-en-27-oic acid (**6**), were isolated from the rhizomes of *Astilbe chinensis*. Their structures were elucidated on the basis of 1D- and 2D-NMR analyses and HR-MS experiments. The isolated compounds exhibited significant cytotoxic activities against the SK-N-SH and HL-60 cell lines.

Keywords: *Astilbe chinensis*; triterpenes; cytotoxic activity

Downloaded At: 18:44 22 January 2011

1. Introduction

Astilbe chinensis (Maxim.) Franch. et Sav. (*A. chinensis*) is a perennial herbaceous plant found in China, Russia, Japan, and Korea. Its rhizomes are used to treat headache, arthralgia, chronic bronchitis, and stomachalgia in traditional Chinese medicine [1–5]. Previous chemical investigations of this plant have identified various compounds, including triterpenes and flavones [6–10].

In our search for bioactive compounds from medicinal herbs, we have studied the chemical constituents and reported two new triterpenes from *A. chinensis* [11]. This paper deals with the isolation and structure elucidation of six new triterpenes, 3β,6β-dihydroxyurs-12-en-27-oic acid (**1**), 3β,6β,24-trihydroxyurs-12-en-27-oic acid (**2**), 3β,6β,7α-trihydroxyurs-12-en-27-oic acid (**3**), 3β-acetoxy-6β-hydroxyurs-12-en-27-oic acid (**4**), 3β,6β,24-trihydroxyolean-12-en-27-oic acid (**5**), and 3β,6β,7α-trihydroxyolean-12-en-27-oic acid (**6**). These compounds were isolated from the rhizomes of *A. chinensis* by screening with antineoplastic tests *in vitro*, and their structures were established by spectroscopic methods, particularly 2D-NMR and HR-MS.

2. Results and discussion

Compound **1** was isolated as a white amorphous powder. The HR-FAB-MS indicated a molecular formula of $C_{30}H_{49}O_4$ at *m/z* 473.3628 $[M + H]^+$, and the IR spectrum revealed the presence of OH (3443 cm^{-1}) and COOH (1698 cm^{-1}) groups. The ^1H NMR spectrum revealed the presence of five tertiary methyls at δ_H 1.34, 1.28, 1.14, 1.01, and 0.88 (each 3H, s), two secondary methyls at δ_H 0.83 (3H, d, $J = 6.5$ Hz) and 0.85 (3H, d, $J = 6.5$ Hz), two oxygenated methine at δ_H 4.42 (1H, brs) and 3.04 (1H, dd, $J = 4.0$, 11.4 Hz), a tri-substituted double bond at δ_H 5.56 (1H, brs). A direct comparison of the ^{13}C NMR spectral data of **1** (Table 2) with those

*Corresponding author. Email: duanhq@tijmu.edu.cn

ISSN 1028-6020 print/ISSN 1477-2213 online
© 2009 Taylor & Francis
DOI: 10.1080/10286020802682866
http://www.informaworld.com

Downloaded At: 18:44 22 January 2011

of the reported compound [3β-hydroxyurs-12-en-27-oic acid] [8] indicated that they had the same skeleton. The difference between these two compounds lay in ring B, and **1** was deduced to be a 6-hydroxyl congener.

The $^{1}H-^{1}H$ COSY spectrum of **1** revealed two separated spin–spin systems (H-2/H-3 and H-5/H-6/H-7) in the A and B rings of the ursene-type skeleton. In the HMBC spectrum, H_3-23 and H_3-24 correlated with the C-3 at δ 80.0, C-4 at δ_C 40.6, and C-5 at δ 56.6; and the H-6 at δ_H 4.42 correlated with the C-5 at δ_C 56.6, C-7 at δ 45.1, C-8 at δ 40.2, and C-10 at δ_C 37.7. Thus, two hydroxyl groups could be located at C-3 and C-6, respectively.

The relative configuration of **1** was determined by extensive analysis of the ^{1}H NMR and NOESY spectra. The 3-OH group should be β-orientated considering the NOE correlations for H-3/H-23 and H-3/H-5, and the coupling constant J (2,3) of 11.4, 4.0 Hz for H-3. The NOE correlation for H-5/H-6 indicated that the 6-OH group was also β-oriented. Thus, the structure of **1** was assigned as 3β,6β-dihydroxyurs-12-en-27-oic acid (Figure 1).

The molecular formula $C_{30}H_{48}O_5$ for **2**, as determined by HR-FAB-MS at m/z 511.3394 $[M + Na]^+$, has one O-atom greater than that of **1**. Comparing the ^{1}H and ^{13}C NMR spectral data to those of **1** (Tables 1 and 2) indicated that **2** had an additional OH group located at C-23 or C-24. This structural deduction was confirmed by HMBC and NOESY experiments: the proton signals at δ_H 3.63 and 4.10 (H_2-24) showed long-range correlations with C-3, C-4, C-5, and C-23, while the signal at δ_H 4.10 (H-24) showed NOE correlation with H_3-25. Thus, the structure of **2** was elucidated as being 3β,6β,24-trihydroxyurs-12-en-27-oic acid (Figure 1).



Figure 1. The structures of compounds **1**–**6**.

Table 1. ^{1}H NMR spectral data for compounds **1–4**.

Position	**1**[a]	**2**[a]	**3**[b]	**4**[b]
1	1.00–1.05 m	1.10–1.20 m	0.95–1.00 m	0.85–0.90 m
	1.60–1.65 m	2.00–2.05 m	1.65–1.70 m	1.70–1.75 m
2	1.60–1.65 m	1.60–1.80 m	1.60–1.80 m	1.20–1.30 m
	1.70–1.75 m			1.70–1.75 m
3	3.04 dd, 4.0, 11.4	3.20 dd, 4.7, 12.0	3.20 dd, 6.7, 8.7	4.43 m
4				
5	0.70 brs	0.85–0.90 m	1.05–1.10 m	0.85–0.90 m
6	4.42 brs	4.34 brs	4.56 brs	4.47 brs
7	1.30–1.40 m	1.30–1.40 m	4.26 d, 3.2	1.35–1.40 m
	1.80–1.90 m	1.90–2.00 m		1.90–1.95 m
8				
9	2.34 dd, 2.4, 9.4	2.41 t, 9.7	1.20–1.25 m	2.31 m
10				
11	2.00–2.10 m	2.00–2.20 m	1.95–2.05 m	2.05–2.15 m
12	5.56 brs	5.57 brs	5.56 brt, 3.2	5.59 brs
13				
14				
15	1.80–1.85 m	1.80–2.00 m	1.75–1.90 m	1.80–1.85 m
	1.95–2.00 m			1.95–2.05 m
16	1.30–1.40 m	1.25–1.35 m	1.25–1.30 m	1.30–1.40 m
			1.90–1.95 m	
17				
18	1.30–1.40 m	1.30–1.40 m	1.40–1.50 m	1.35–1.40 m
19	0.80–0.90 m	0.75–0.85 m	0.90–0.95 m	0.80–0.90 m
20	0.80–0.85 m	0.70–0.80 m	0.95–1.00 m	0.80–0.90 m
21	1.30–1.35 m	1.40–1.45 m	1.30–1.35 m	1.30–1.40 m
	2.10–2.15 m	2.00–2.05 m	1.95–2.00 m	2.00–2.05 m
22	1.20–1.25 m	1.25–1.30 m	1.20–1.25 m	1.20–1.25 m
	1.40–1.50 m	1.35–1.40 m	1.30–1.35 m	1.40–1.45 m
23	1.01 s	1.14 s	1.08 s	0.92 s
24	1.14 s	3.63 d, 11.4, 4.10 d, 11.4	1.18 s	1.23 s
25	1.34 s	1.39 s	0.92 s	1.37 s
26	1.28 s	1.29 s	1.21 s	1.29 s
27				
28	0.88 s	0.84 s	0.83 s	0.84 s
29	0.83 d, 6.5	0.84 d, 6.0	0.76 d, 6.4	0.83 d, 6.5
30	0.85 d, 6.5	0.89 d, 6.2	0.95 d, 6.1	0.85 d, 6.5

[a] CD_3OD.
[b] $CDCl_3$.

Downloaded At: 18:44 22 January 2011

Compound **3** had the same molecular formula ($C_{30}H_{48}O_5$) as **2**, and its ^{13}C NMR spectral data were similar to those of **2** (Table 2), except for an oxygenated methine (δ_C 82.9) in **3**. The $^1H-^1H$ COSY correlation of H-5/H-6/H-7 and the HMBC correlations of H-7 with C-5, C-6, C-8, and C-9 indicated that **3** was the 24-dehydroxy-6-hydroxy derivative of **2**. In the NOESY spectrum, the proton signal of H-7 correlated with H_3-26, and H_3-23 correlated with H-3, H-5, and H-6. Therefore, the OH groups possessed the 3β, 6β, and 7α configurations. Thus, the structure of **3** was assigned as 3β,6β,7α-trihydroxyurs-12-en-27-oic acid.

Compound **4** possessed the molecular formula $C_{32}H_{50}O_5$, as determined by HR-FAB-MS. Its ^{13}C NMR spectral data were similar to those of **1** (Table 2), except for an additional acetyl group. Compound **4** was assumed to be a 3-OAc congener of **1**. The HMBC correlations from H-3 (δ_H 4.43) to the ketone carbon of the acetyl group supported this conclusion. Accordingly, the structure of

Downloaded At: 18:44 22 January 2011

Table 2. ^{13}C NMR spectral data for compounds **1**–**4**.

Position	**1**[a]	**2**[a]	**3**[b]	**4**[b]
1	42.1	42.4	39.2	40.4
2	28.1	27.9	27.2	23.7
3	80.0	80.2	78.5	80.9
4	40.6	45.8	39.1	38.5
5	56.6	57.7	49.9	55.1
6	68.4	67.4	67.9	68.2
7	45.1	43.1	82.9	44.0
8	40.2	40.1	43.1	39.2
9	48.4	48.8	49.8	47.0
10	37.7	37.8	35.8	36.5
11	23.9	23.9	21.4	22.6
12	129.7	129.7	130.1	128.9
13	134.3	134.6	131.3	132.4
14	57.7	57.9	56.1	56.2
15	23.6	23.7	23.1	22.4
16	31.6	30.5	27.1	28.9
17	34.8	34.9	33.5	33.7
18	61.7	61.9	60.0	60.2
19	40.9	41.1	39.2	39.6
20	38.8	38.9	36.2	37.6
21	30.4	31.8	30.8	30.4
22	42.2	42.3	41.1	40.9
23	28.5	22.8	27.2	27.9
24	17.5	64.2	17.4	18.3
25	18.1	18.1	10.9	17.7
26	20.5	20.5	12.9	19.9
27	179.4	179.3	176.9	179.9
28	29.7	29.8	28.6	28.9
29	18.6	18.6	17.9	17.9
30	21.8	21.8	21.0	21.3

[a] Measured in CD_3OD.
[b] Measured in $CDCl_3$.

4 was determined to be 3β-acetoxy-6β-hydroxyurs-12-en-27-oic acid (Figure 1).

Compound **5** was isolated as an amorphous powder. Its HR-FAB-MS revealed a quasi-molecular ion at *m/z* 511.3349 $[M + Na]^+$, indicating a molecular formula of $C_{30}H_{48}O_5$. The IR spectrum revealed the presence of OH ($3385\,cm^{-1}$) and COOH ($1687\,cm^{-1}$) groups. The ^{1}H NMR spectral data of **5** (Table 3) showed signals including six methyls, two oxygenated methines, one oxygenated methylene, and a vinyl proton. The ^{13}C NMR spectral data of **5** (Table 3) were similar to those of the reported compound [3β,6β-dihydroxyolean-12-en-27-oic acid] [9], and was deduced to be a 24-hydroxy congener. In the HMBC spectrum, H_2-24 (δ_H 3.62 and 4.09) correlated with C-3, C-4, C-5, and C-23; and H_3-23 correlated with C-3, C-4, C-5, and C-24. In addition, H-24 (δ_H 4.09) showed NOE correlation with H_3-25, and H_3-23 correlated with H-3, H-5, and H-6. From these observations, the structure of **5** was determined as being 3β,6β,24-trihydroxy-olean-12-en-27-oic acid.

Compound **6** had the same molecular formula as **5**, and the ^{1}H and ^{13}C NMR spectral data of **6** were similar to those of **5**, except for the location of an OH group. The HMBC correlations from H-7 (δ_H 4.28) to C-5, C-6, C-8, and C-9 suggested that the OH group was located at C-7. The relative configurations of **6** were determined by the same method as that described above. Accordingly, the structure of **6** was determined to be 3β,6β,7α-trihydroxyolean-12-en-27-oic acid (Figure 1).

The antineoplastic activities of compounds **1**–**6** were determined by using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) colorimetric assay with two tumor cell lines: the human neuroblastoma cell line (SK-N-SH) and the human leukemia cell line (HL-60). Compounds **1**–**6** exhibited significant cytotoxic activity against these tumor cells *in vitro* (Table 4).

3. Experimental

3.1 General experimental procedures

The IR spectrum was detected by a Perkin-Elmer 577 spectrometer (in cm^{-1}) and optical rotations were obtained on a Perkin-Elmer 241-MC digital polarimeter. The NMR analysis of samples was performed with a Bruker Avance 300 instrument (^{1}H NMR, 300 MHz ^{13}C NMR and, 75 MHz), both with tetramethylsilane as an internal standard. HR-EI-MS data and EI-MS data were obtained on a JEOL JMS-SX102A instrument (in *m/z*). Column chromatography was performed on silica gel (Qingdao Haiyang Chemical Co. Ltd, Qingdao, China) and Toyopearl HW-40 (TOSOH). HPLC was a JASCO Gulliver Series with PU-2089 (pump), RI-2031, and

Table 3. ^{1}H and ^{13}C NMR spectral data of compounds **5** and **6**.

	5[a]		**6**[b]	
Position	^{1}H	^{13}C	^{1}H	^{13}C
1	1.25–1.30 m	42.4	1.25–1.30 m	39.3
	1.55–1.60 m		1.55–1.60 m	
2	1.60–1.80 m	27.9	1.60–1.80 m	27.1
3	3.18 m	80.2	3.17 dd, 6.9, 8.9	78.5
4		45.8		39.1
5	0.80–0.85 m	57.8	1.05–1.10 m	49.9
6	4.34 brs	67.3	4.56 brs	67.9
7	1.35–1.40 m	42.9	4.28 d, 3.0	82.8
	1.95–2.00 m			
8		40.1		43.0
9	1.35–1.45 m	49.0	1.20–1.30 m	49.6
10		37.8		35.9
11	1.95–2.05 m	24.1	1.90–2.00 m	21.4
12	5.61 brs	127.0	5.64 brt, 3.5	127.8
13		138.5		134.2
14		57.6		56.2
15	1.60–1.65 m	23.5	1.60–1.65 m	22.9
	1.85–1.90 m		1.90–1.95 m	
16	1.60–1.65 m	29.0	1.65–1.70 m	26.6
	2.00–2.05 m		2.05–2.11 m	
17		34.1		34.4
18	2.00–2.05 m	50.7	2.00–2.10 m	48.4
19	0.95–1.00 m	45.5	0.90–1.00 m	42.5
	2.27 dd, 1.8, 6.6		2.61 t, 13.8	
20		32.1		30.8
21	1.10–1.15 m	35.7	1.10–1.15 m	34.4
	1.35–1.40 m		1.35–1.40 m	
22	1.30–1.35 m	37.9	1.20–1.30 m	36.7
	1.45–1.50 m		1.50–1.55 m	
23	1.13 s	22.8	1.08 s	27.2
24	3.62 d, 11.4	64.1	1.18 s	17.4
	4.09 d, 11.4			
25	1.39 s	18.0	1.28 s	17.9
26	1.28 s	20.3	1.19 s	12.6
27		180.1		177.5
28	0.88 s	28.9	0.86 s	28.3
29	0.85 s	33.9	0.94 s	33.0
30	0.87 s	24.2	0.88 s	24.0

[a] Measured in CD_3OD.
[b] Measured in $CDCl_3$.

UV-2075 (detector). Preparative HPLC column was used as ODS (YMC-Pack ODS-A, SH-343-5).

3.2 Plant material

The rhizomes of *A. chinensis* (Maxim.) Franch. et Sav. were collected in November 2003 from Hefeng, Hubei Province, China. The plant material was identified by Prof. Ding-Rong Wan, School of Life Sciences, South-Central University for Nationalities. A voucher specimen (No. D20030802) has been deposited at the School of Pharmaceutical Sciences, Tianjin Medical University, China.

3.3 Extraction and isolation

The dried rhizomes (3.2 kg) of *A. chinensis* were crushed and extracted three times with

Downloaded At: 18:44 22 January 2011

Downloaded At: 18:44 22 January 2011

Table 4. Cytotoxic activities of compounds **1**–**6**.

	IC_{50} (μg/ml)	
Compound	SK-N-SH	HL-60
1	26.42	10.19
2	31.82	18.41
3	44.28	19.04
4	17.45	19.44
5	17.94	37.00
6	34.98	38.19
5-FU[a]	0.72	
ATRA[b]		1.56

[a] Fluorouracil.
[b] All-*trans* retinoic acid.

95% EtOH (10 l) for 6 h under reflux (3×), and then concentrated *in vacuo* to afford a residue (1115 g), which was suspended in H_2O and then separately partitioned with petroleum ether (PE), EtOAc, and *n*-BuOH. The PE extract (20 g) was separated by column chromatography (1 kg silica gel; PE/EtOAc 10:1, 8:1, 6:1, 3:1, 2:1, 1:1, 1:2, and 1:3), EtOAc, EtOAc–MeOH (19:1 and 10:1), MeOH to yield 17 fractions (1–17). Fraction 8 (3.6 g) was chromatographed on silica gel [$CHCl_3$–MeOH (97:3 and 93:7)] to afford five fractions (8.1–8.5). Fraction 8.2 was chromatographed by column chromatography (Toyopearl HW-40; $CHCl_3$/MeOH, 2:1) to afford four fractions (8.2.1–8.2.4). Fraction 8.2.2 was purified by HPLC (ODS-A, eluted with MeOH/H_2O, 9:1, 3.0 ml/min) to afford **1** (78.8 mg) and **4** (27.3 mg). Fraction 8.3 was chromatographed by column chromatography (Toyopearl HW-40) to afford four fractions (8.3.1–8.3.4). Fraction 8.3.2 was purified by HPLC (ODS-A, eluted with MeOH/H_2O, 9:1, 3.0 ml/min) to afford **2** (40.1 mg), **3** (7.4 mg), **5** (25.4 mg), and **6** (15.8 mg).

*3.3.1 3β,6β-Dihydroxyurs-12-en-27-oic acid (**1**)*

Amorphous powder; $[\alpha]_D^{25}+87.1$ ($c = 1.2$, MeOH). IR max (KBr): 3443, 2994, 2864, 1698, 1456, 1375, 1224, 1096, 1015, and 921 cm^{-1}. ^1H and ^{13}C NMR spectral data, see Tables 1 and 2. HR-FAB-MS *m/z*: 473.3628 $[M+H]^+$ (calcd for $C_{30}H_{49}O_4$, 473.3631).

*3.3.2 3β,6β,24-Trihydroxyurs-12-en-27-oic acid (**2**)*

Amorphous powder; $[\alpha]_D^{25}+93.2$ ($c = 1.15$, MeOH). IR max (KBr): 3385, 2925, 1687, 1455, 1374, 1232, 1059, 916, and 885 cm^{-1}. ^1H and ^{13}C NMR spectral data, see Tables 1 and 2. HR-FAB-MS *m/z*: 511.3394 $[M+Na]^+$ (calcd for $C_{30}H_{48}O_5Na$, 511.3399).

*3.3.3 3β,6β,7α-Trihydroxyurs-12-en-27-oic acid (**3**)*

Amorphous powder; $[\alpha]_D^{25} = 17.2$ (c=0.62, MeOH). IR max (KBr): 3494, 3352, 2927, 1750, 1459, 1369, 1173, 1135, 1073, 1031, and 882 cm^{-1}. ^1H and ^{13}C NMR spectral data, see Tables 1 and 2. HR-FAB-MS *m/z*: 471.3477 $[M+H-H_2O]^+$ (calcd for $C_{30}H_{47}O_4$, 471.3474).

*3.3.4 3β-Acetoxy-6β-hydroxyurs-12-en-27-oic acid (**4**)*

Amorphous powder; $[\alpha]_D^{25}+66.9$ ($c = 1.09$, CH_3Cl). IR max (KBr): 3531, 2951, 1716, 1686, 1377, 1267, 1036, 985, 832, and 758 cm^{-1}. ^1H and ^{13}C NMR spectral data, see Tables 1 and 2. HR-FAB-MS *m/z*: 537.3526 $[M+Na]^+$ (calcd for $C_{32}H_{50}O_5Na$, 537.3556).

*3.3.5 3β,6β,24-Trihydroxyolean-12-en-27-oic acid (**5**)*

Amorphous powder; $[\alpha]_D^{25}+91.5$ (c = 1.15, MeOH). IR max (KBr): 3379, 2924, 1676, 1466, 1363, 1263, 1065, 1018, and 1001 cm^{-1}. ^1H and ^{13}C NMR spectral data, see Table 3. HR-FAB-MS: *m/z* 511.3349 $[M+Na]^+$ (calcd for $C_{30}H_{48}O_5Na$, 511.3399).

*3.3.6 3β,6β,7α-Trihydroxyolean-12-en-27-oic acid (**6**)*

Amorphous powder; $[\alpha]_D^{25}+27.3$ ($c = 0.67$, MeOH). IR max (KBr): 3451, 2928, 1756, 1467, 1387, 1259, 1132, 1083, 1009, and

936 cm^{-1}. ^{1}H and ^{13}C NMR spectral data, see Table 3. HR-FAB-MS: *m/z*: 471.3515 $[M+H-H_2O]^+$ (calcd for $C_{30}H_{47}O_4$, 471.3474).

3.4 Procedure of bioassay

The cytotoxicities of compounds **1**–**6** were assayed in two cell lines: the human neuroblastoma cell line (SK-N-SH) and human leukemic cell line (HL-60). One hundred and eighty microliters of the cell suspensions (5×10^4 cells/ml) were seeded in 96-well microplates, and incubated for 24 h in order to allow cell attachment. The tested compound solutions were then added to the cell cultures at final concentrations of 3.12, 6.25, 12.50, 25.00, 50.00, and 100.00 μg/ml, and the cells were incubated (37°C, 5% CO_2) for 72 h. The supernatants were then removed using a micropipette, and 100 μl of MTT solution (0.5 mg/ml) were added to each well of the 96-well plates, followed by incubation for 4 h. Subsequently, the cell culture medium was removed by pipetting and the purple formazan crystals were dissolved by adding 100 μl of DMSO to each well. The optical density was read at a wavelength of 490 nm using a microplate reader.

Acknowledgements

This project was supported by the grants from the Scientific Research Foundation, Tianjin Medical University, Tianjin, and the Postdoctoral Science Foundation of China (No. 20070410546).

References

[1] J.T. Pan, *Acta Phytotaxon. Sin.* **23**, 432 (1985).
[2] J.T. Pan, *Acta Phytotaxon. Sin.* **33**, 390 (1995).
[3] Jiangsu New Medical College, *Dictionary of Traditional Chinese Medicines* (Shanghai People's Press, Shanghai, 1977), p. 2324.
[4] M. Kubo, Y. Kimura, and T. Namba, *Yakushigaku Zasshi* **10**, 34 (1975).
[5] P.F. Chen, P.F. Lai, and P. Zhang, *China J. Chin. Mater. Med.* **21**, 302 (1996).
[6] H. Chen, T. Chen, and J.X. Li, *China J. Chin. Mater. Med.* **29**, 652 (2004).
[7] K. Takahashi, K. Kanayama, and Y. Tanabe, *Chem. Pharm. Bull.* **20**, 2106 (1972).
[8] H.X. Sun, J.X. Zhang, Y.P. Ye, Y.J. Pan, and Y.A. Shen, *Helv. Chim. Acta* **86**, 2414 (2003).
[9] H.X. Sun, Y.P. Ye, K.W. Wang, and Y.J. Pan, *Acta Crystallogr. Sect. E* **59**, o989 (2003).
[10] H.X. Sun and Y.J. Pan, *Acta Crystallogr. Sect. C* **60**, o300 (2004).
[11] J.Y. Hu, Z. Yao, J. Teng, Y. Takaishi, and H.Q. Duan, *Chin. Chem. Lett.* **17**, 628 (2006).

Downloaded At: 18:44 22 January 2011